Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Jay R. Luly Buys 45,000 Shares of Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Jay R. Luly purchased 45,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 12th. The stock was acquired at an average cost of $5.69 per share, with a total value of $256,050.00. Following the purchase, the chief executive officer now directly owns 846,638 shares of the company’s stock, valued at $4,817,370.22. This trade represents a 5.61 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ ENTA opened at $5.86 on Thursday. The company has a 50 day simple moving average of $5.80 and a two-hundred day simple moving average of $9.54. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $17.80. The company has a market capitalization of $124.99 million, a price-to-earnings ratio of -1.07 and a beta of 0.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. On average, analysts forecast that Enanta Pharmaceuticals, Inc. will post -5.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ENTA shares. StockNews.com cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday. JMP Securities reiterated a “market outperform” rating and set a $21.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday. Finally, Robert W. Baird lowered their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. Two research analysts have rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $17.25.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several large investors have recently modified their holdings of ENTA. China Universal Asset Management Co. Ltd. purchased a new stake in Enanta Pharmaceuticals during the 4th quarter valued at about $26,000. US Bancorp DE lifted its stake in shares of Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after buying an additional 4,243 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Enanta Pharmaceuticals during the fourth quarter valued at approximately $58,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Enanta Pharmaceuticals during the third quarter valued at approximately $122,000. Finally, AlphaQuest LLC raised its holdings in Enanta Pharmaceuticals by 16.4% in the 4th quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 3,137 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.